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Mice have been extensively employed as an animal model of renal damage caused by Shiga toxins. In this
study, we examined the role of the proinflammatory cytokine tumor necrosis factor alpha (TNF-) in the
development of toxin-mediated renal disease in mice. Mice pretreated with TNF- and challenged with Shiga
toxin type 1 (Stx1) showed increased survival compared to that of mice treated with Stx1 alone. Conversely,
mice treated with Stx1 before TNF- administration succumbed more quickly than mice given Stx1 alone.
Increased lethality in mice treated with Stx1 followed by TNF- was associated with evidence of glomerular
damage and the loss of renal function. No differences in renal histopathology were noted between animals
treated with Stx1 alone and the TNF- pretreatment group, although we noted a sparing of renal function when
TNF- was administered before toxin. Compared to that of treatment with Stx1 alone, treatment with TNF-
after toxin altered the renal cytokine profile so that the expression of proinflammatory cytokines TNF- and
interleukin-1 (IL-1) increased, and the expression of the anti-inflammatory cytokine IL-10 decreased.
Increased lethality in mice treated with Stx1 followed by TNF- was associated with higher numbers of
dUTP-biotin nick end labeling-positive renal tubule cells, suggesting that increased lethality involved enhanced
apoptosis. These data suggest that the early administration of TNF- is a candidate interventional strategy
blocking disease progression, while TNF- production after intoxication exacerbates disease.
Shiga toxins are a family of genetically and functionally re-
lated cytotoxic proteins expressed by the enteric pathogens
Shigella dysenteriae serotype 1 and certain serotypes of Esche-
richia coli. Antigenic similarity to Shiga toxin expressed by S.
dysenteriae serotype 1 is used to define Shiga toxin type 1 (Stx1)
and type 2 (Stx2) expressed by Shiga toxin-producing E. coli
(STEC) (44). Shiga toxins consist of a single A subunit in
noncovalent association with a pentamer of B subunits. B sub-
units mediate binding to the neutral glycolipid receptor glo-
botriaosylceramide (Gb3), while the A subunit possesses an
N-glycosidase activity (38). Following toxin internalization and
routing to the endoplasmic reticulum (ER), a fragment of the
toxin A subunit generated by furin or a furin-like protease is
translocated across the ER membrane and mediates the cleav-
age of a single adenine residue (A4256 in the rat) from the 28S
rRNA component of ribosomes (39). Stx-induced depurination
leads to the disruption of elongation factor-dependent amino-
acyl-tRNA binding to nascent polypeptides (30). Thus, Shiga
toxins are potent protein synthesis inhibitors, with 50% cyto-
toxic doses measured in pg/ml amounts for many cell types in
vitro. Shiga toxins also activate the ribotoxic and ER stress path-
ways, which are important in the activation of proinflammatory
cytokine/chemokine production and apoptosis (6, 22, 41).
The ingestion of small quantities of Stx-producing bacteria
may lead to the development of bloody diarrhea with progres-
sion to acute renal failure, designated diarrhea-associated he-
molytic uremic syndrome (DHUS) (33). Epidemiologic stud-
ies have shown that the ingestion of STEC strains expressing
Stx2 alone or Stx1 and Stx2 are more likely to progress to
life-threatening extraintestinal complications (3, 17, 31).
DHUS is a leading cause of pediatric acute renal failure.
DHUS is characterized by rapid-onset oligouria or anuria,
azotemia, microangiopathic hemolytic anemia with schistocy-
tosis, and thrombocytopenia (33, 47). The histopathological ex-
amination of DHUS renal tissues showed that glomerular mi-
crovascular endothelial cells were frequently swollen and
detached from the basement membrane, and glomerular capillary
lumina may be occluded with fibrin-rich microthrombi (21, 36).
Numerous animal models have been employed to character-
ize the role of Stx1 and Stx2 in pathogenesis. Studies utilizing
nonhuman primates showed that Shiga toxins are essential
virulence determinants in the development of microangio-
pathic lesions. Fontaine et al. (9) showed that macaque mon-
keys fed toxigenic strains of S. dysenteriae developed colonic
microvascular lesions, while baboons given purified intrave-
nous Stx1 developed acute renal failure (48). The bolus intra-
venous administration of Stx1 or Stx2 into baboons revealed
that the animals were more sensitive to Stx2, although the
mean times to death were prolonged in Stx2-treated animals
compared to that with Stx1 treatment. Both toxins mediated
hematologic changes such as thrombocytopenia and schistocy-
tosis, and both toxins produced renal pathology, but with dif-
ferent presentations. Renal damage caused by Stx1 was char-
acterized by moderate congestion at the cortico-medullary
junction, while Stx2-treated animals showed severe medullary
congestion with cortical ischemia (42). Mice fed Stx2-produc-
ing E. coli or given a single bolus injection of purified Shiga
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toxins died without the development of glomerular thrombotic
microangiopathy (50, 54). However, the administration of mul-
tiple low doses of Stx2 allowed the animals to survive initial
toxin challenge and develop glomerular lesions characteristic
of HUS in humans (40). In addition to the toxins, host re-
sponse factors may contribute to DHUS pathogenesis. Pro-
dromal hemorrhagic colitis may alter normal colonic barrier
function, and patients with DHUS may be endotoxemic or
show evidence of elevated antibody titers against lipopolysac-
charides (LPS) expressed by Stx-producing E. coli (2, 10, 26).
LPS elicit the expression of a broad array of pro- and anti-
inflammatory cytokines and chemokines (45). In accordance
with this, DHUS patients frequently have increased serum or
urinary proinflammatory cytokine and chemokine levels (15,
23). Studies using small-animal models support the hypothesis
that additional bacterial and host response factors facilitate the
development of renal disease. Keepers et al. (19) demon-
strated that the coadministration of Stx2 and LPS to C57BL/6
mice did not produce major changes in lethality but resulted in
pathophysiological changes more consistent with disease in
humans: intraglomerular platelet and fibrin deposition, de-
creased renal function, neutrophilia, and lymphocytopenia.
Barrett et al. (1) showed that the timing of toxin and LPS
challenges were critical in disease outcome. LPS enhanced the
lethal effects of purified Stx2 when administered to rabbits or
mice after toxin challenge, whereas LPS protected the animals
from Stx2 toxicity when administered before the toxin. Pal-
ermo et al. (32) showed that the LPS-induced modulation of
Stx2 lethality was cytokine time and dose dependent. Mice
given low doses of TNF- or IL-1 1 h before Stx2 treatment
showed increased lethality when treated with Stx2, while mice
given higher doses of IL-1 (sufficient to elicit corticosteroid
production) were protected from Stx2 lethality.
The proinflammatory cytokines TNF- and IL-1 sensitize
vascular endothelial cells to the cytotoxic action of Shiga toxins
in vitro (24, 34, 53) through a mechanism involving the in-
creased expression of genes involved in the biosynthesis of Gb3
(43). Murine and human macrophages or macrophage-like cell
lines express proinflammatory cytokines and chemokines when
treated with purified Shiga toxins (12, 35, 51). Keepers et al.
(18) showed a marked monocytic cell infiltrate into the kidneys
of mice given Stx2 and LPS. Collectively, these data suggest
that the innate immune response to Shiga toxins, in the pres-
ence or absence of LPS, alters the outcome of renal disease. In
the present study, we have examined the role of a single proin-
flammatory cytokine, TNF-, in pathogenesis using the mouse
model of Stx-induced renal damage. Our data suggest that the
timing of TNF- production affects the outcome of disease in that
the presence of elevated TNF- levels prior to toxin challenge
protects animals from disease, while high TNF- levels occurring
after toxin administration result in accelerated lethality.
MATERIALS AND METHODS
Mice. Male C3H/HeN mice weighing approximately 20 g were purchased from
Taconic Farms and housed in the College of Medicine Animal Facilities, Texas
A&M Health Science Center. All animals were documented to be specific patho-
gen free by the supplier, and sentinel animals were routinely used to test for the
presence of murine pathogens. Animal rooms were temperature controlled and
on a 12-h light/12-h dark cycle. Animals were allowed access to food and water
ad libitum. All experimental procedures complied with the Guide for Care and
Use of Laboratory Animals and were approved by the Texas A&M University
Laboratory Animal Care Committee.
Shiga toxins. Stx1 was expressed from E. coli DH5(pCKS112), a recombinant
strain containing a plasmid encoding the stx1 operon (50). Stx1 in crude bacterial
lysates was purified by sequential ion-exchange, chromatofocusing, and immu-
noaffinity chromatography. Toxin purity was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with silver staining and by
Western blotting using bovine polyclonal Stx1-specific antisera (a kind gift from
James Samuel, Texas A&M Health Science Center, College Station, TX). Toxin
preparations were passed through ActiClean Etox columns (Sterogene Biosepa-
rations, Carlsbad, CA) to remove trace endotoxin contaminants and were deter-
mined to contain less than 0.1 ng of endotoxin per ml by the Limulus amoebocyte
lysate assay (Associates of Cape Cod, East Falmouth, MA). Purified Stx2 was
obtained from BEI Resources, Manassas, VA.
Survival studies. Animals were injected with either Stx1, Stx2, recombinant
murine TNF- (rmTNF-) (R&D Systems, Minneapolis, MN), or saline, as
indicated, via the intraperitoneal (i.p.) route. Treatment groups were randomly
assigned and categorized based on the timing of rmTNF- injection relative to
toxin exposure (Fig. 1). Mice pretreated with rmTNF- prior to Stx1 or Stx2
injection were designated TNF- pretreatment groups. Briefly, mice were in-
jected with 2.0 g rmTNF- at 24, 6, or 1 h before the administration of 9 g/kg
of body weight Stx1 or 10 ng/kg Stx2 and were monitored for survival. Mice
receiving Stx1 prior to rmTNF- injection were designated TNF- posttreatment
groups (Fig. 1). These groups were administered 9 g/kg of Stx1 and subse-
quently injected with 2.0 g rmTNF- at 1, 6, and 24 h after toxin injection and
monitored for survival. All mice were euthanized by CO2 asphyxiation upon signs
of morbidity (ruffled fur, lethargy, and hind-limb paralysis). Neutralizing anti-
bodies were used to protect TNF- posttreated animals from increased lethality.
Briefly, mice were given either 4.0 g anti-rmTNF- (R&D Systems, Minneap-
olis, MN) or 60 ng anti-Stx1 (13C4; Hycult Biotechnology, Uden, The Nether-
lands). One hour later, the mice were challenged with 4.5 g/kg of Stx1 followed
by 2.0 g rmTNF- and monitored for survival during a 7-day period. All
statistical significance was assessed by the log-rank (Mantel-Cox) test using
Graphpad Prism version 5 for Mac OS X (Graphpad Software, San Diego, CA).
Histopathology studies. The histopathology protocol of Chen et al. (5) was
followed. Briefly, mice were euthanized by CO2 asphyxiation 48 h after Stx1
injection (Fig. 1). Kidney halves (right side) were immediately placed in 4%
paraformaldehyde for 24 h. After being rinsed with phosphate-buffered saline
(PBS), tissues were placed in 70% ethanol for 24 h and were passed through a
series of increasing concentrations of alcohol washes followed by xylene, and
finally they were embedded in paraffin wax. Five-m sections were prepared, and
hematoxylin and eosin (H&E) staining was performed. Pathology was evaluated
in a blinded manner by a trained veterinary pathologist. Glomerular changes
were quantified by randomly counting 10 glomeruli per high-power field for five
independent sections from three animals and were scored as hyperemic/occluded
versus normal. Total numbers of glomeruli per field also were counted. Statistical
significance was assessed by one-way analysis of variance (ANOVA) with Tukey’s
FIG. 1. TNF- pre- and posttreatment protocols for survival, his-
tology, and apoptosis studies. (A) Pretreatment. Mice received 2.0 g
rmTNF- at 24, 6, or 1 h before injection with either 9 g/kg Stx1 or
10 ng/kg Stx2 at time zero. Subsequently, mice were monitored for
morbidity (survival curves) or euthanized 48 h after Stx injection (his-
tology, TUNEL staining). (B) Posttreatment. Mice received 9 g/kg of
Stx1 at time zero. One, 6, and 24 h later, mice were given 2.0 g
rmTNF- and monitored for morbidity (survival curves) or euthanized
48 h after Stx1 injection (histology, TUNEL staining).
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multiple comparison test using Graphpad Prism version 5 for Mac OS X (Graph-
pad Software, San Diego, CA).
Blood chemistries. Mice were treated with Stx1 alone, rmTNF- 6 h before
Stx1 challenge (TNF- pretreatment group), or rmTNF- 6 h after Stx1 chal-
lenge (TNF- posttreatment group). On day 2, blood was collected from mice via
cardiac puncture in heparin-coated tubes and analyzed at the Clinical Pathology
Veterinary Medical Laboratory at Texas A&M University, College Station, TX.
White blood cell (WBC) differentials were conducted using a Coulter Z1 particle
counter (Beckman Coulter, Fullerton, CA). Blood urea nitrogen (BUN) and
serum creatinine levels were analyzed using a Vitros 250 instrument (Ortho
Clinical Diagnostics, Rochester, NY). Statistical significance was assessed using
the nonparametric one-way ANOVA Kruskal-Wallis test with Dunn’s multiple
comparison test using Graphpad Prism version 5 (Graphpad Software).
Analysis of cytokine expression. Kidneys (left side) were harvested from mice
at various time points (Fig. 2), and kidney halves were placed in 250 l radio-
immunoprecipitation assay (RIPA) lysis buffer and homogenized. Lysates were
centrifuged at 15,000  g for 30 min. Supernatants were collected and stored at
80°C until analyzed. Levels of IL-1, IL-2, IL-4, IL-5, IL-10, IFN-, TNF-,
and granulocyte-macrophage colony-stimulating factor (GM-CSF) were deter-
mined using a Bio-Plex suspension array system (Bio-Rad Laboratories, Hercu-
les, CA) and commercially available kits according to the manufacturer’s instruc-
tions. A series of eight standards ranging in concentrations from 32,000 to 1.95
pg/ml were included in each assay. Samples were analyzed in duplicate and
graphed using GraphPad Prism. Statistical significance was assessed at P  0.05
by one-way ANOVA with Tukey’s multiple comparison test using Graphpad
Prism version 5 (Graphpad Software).
TUNEL staining. Kidneys were harvested from animals 48 h after treatment
(Fig. 1) and placed in 4% paraformaldehyde for 24 h. After being rinsed with
PBS, the tissues were placed in 70% ethanol for 24 h and then embedded in
paraffin. Five-m sections were collected, and terminal deoxynucleotidyltrans-
ferase-mediated dUTP-biotin nick end labeling (TUNEL) staining (Roche,
Mannheim, Germany) was performed according to the manufacturer’s protocol.
Briefly, sections were dewaxed by several washes in undiluted xylene followed by
rehydration in ethanol washes (100, 95, 90, 80, and 70%). Slides then were
washed with PBS and incubated with a permeabilization solution (0.1% Triton
X-100, 0.1% sodium citrate) for 8 min. A TUNEL reaction mixture was added to
slides and allowed to incubate in a humidified chamber for 1 h at 37°C. Slides
were imaged using a Nikon fluorescent microscope. Images were captured with
an excitation wavelength in the range of 450 to 500 nm and detection in the range
of 515 to 565 nm. TUNEL-positive cells were quantified by counting stained cells
per high-power field from three independent slides from three animals. Statis-
tical significance was assessed at P  0.05 using one-way ANOVA with Tukey’s
multiple comparison test using Graphpad Prism version 5 (Graphpad Software).
RESULTS
Treatment of mice with TNF- alters Stx1 lethality. TNF-
has been shown to upregulate the expression of the toxin
receptor Gb3 by human endothelial cells in vitro (43). There-
fore, we hypothesized that the pretreatment of mice with
rmTNF- followed by Stx1 challenge would sensitize the ani-
mals for increased vascular damage, resulting in increased le-
thality. Mice were treated with Stx1 alone, rmTNF- alone, or
with rmTNF- followed by the injection of 9 g/kg Stx1
(TNF- pretreatment group), and then they were monitored
for survival for 7 days (Fig. 3A). Mice receiving Stx1 alone
displayed a mean time to death of 4 days, while the rmTNF-
dose used in this study did not cause lethality. Mice pretreated
with rmTNF- for as little as 1 h before Stx1 administration
were protected from the lethal effects of the toxin, with survival
rates of 80% during 7 days (P  0.001). Mice pretreated with
rmTNF- for 6 or 24 h prior to Stx1 treatment had 90%
survival rates throughout the monitored time course (P 
0.001). Since HUS in humans is more likely following the
ingestion of STEC expressing Stx2, we also examined the ef-
fects of rmTNF- pretreatment on the lethality of mice given
10 ng/kg of Stx2 (Fig. 3B). In accordance with earlier studies
(50), we show that lethality is mediated by lower doses of Stx2
compared to that of Stx1, and the mean time to death in
Stx2-treated animals was prolonged to approximately 5 days.
Pretreatment with rmTNF- was able to rescue Stx2-chal-
lenged mice as well, although the protection was not as effec-
tive as that seen in Stx1-treated animals. Mice that were pre-
treated at 6 and 24 h before Stx2 administration had a survival
rate of approximately 30 and 20%, respectively. Mice pre-
treated with rmTNF- for 1 h before Stx2 exposure had a
survival rate of 80% (P  0.01). Since rmTNF- pretreatment
manifested increased survival in Stx1- and Stx2-treated mice,
we used Stx1 in the remaining experiments.
We also examined the effects on the lethality of mice given
rmTNF- after exposure to Stx1 (Fig. 3C, TNF- posttreat-
ment group). Mice given Stx1 before rmTNF- showed modest
decreases in mean times to death, with 50% of the animals
receiving rmTNF- 1 h after Stx1 dying by day 2 (P 0.05). By
day 4, all mice that received rmTNF- after toxin exposure
were dead. We attempted to rescue TNF--posttreated ani-
mals from death using anti-Stx1 and anti-rmTNF- neutraliz-
ing antibodies (Fig. 3D). We were unable to protect mice from
the heightened lethality we observed when mice were treated
with rmTNF- after 9 g/kg of Stx1 (data not shown). There-
fore, antibody neutralization experiments were done using 4.5
g/kg of Stx1. Mice exposed to this dose of Stx1 displayed a
mean time to death of approximately 5 days, while mice that
were TNF- posttreated all died by day 3 (P  0.001). The
administration of anti-Stx1 or anti-rmTNF- to TNF--post-
treated animals resulted in increased survival times for both
groups (P  0.01 and P  0.05, respectively). However, ani-
mals treated with anti-Stx1 displayed a greater percentage of
survival than mice treated with anti-TNF- (40 and 20% sur-
vival, respectively) during the 7-day monitoring period. When
anti-TNF- and anti-Stx1 antibodies were coadministered,
FIG. 2. TNF- pre- and posttreatment protocols for cytokine anal-
ysis. (A) Pretreatment. Mice were injected with 2.0 g rmTNF-, and
6 h later they were injected with 9 g/kg of Stx1. Kidneys were har-
vested at various time points and homogenized for cytokine analysis.
(B) Posttreatment. Mice were injected with 9 g/kg of Stx1 at time
zero. Six hours later they were given 2.0 g rmTNF-, and at various
time points kidneys were harvested and homogenized for cytokine
analysis.
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40% of the mice survived Stx1 and TNF- posttreatment chal-
lenge (P  0.01). All mice survived treatment with anti-TNF-
and anti-Stx1 alone (data not shown). Collectively, these data
suggest that the timing of TNF- exposure alters the patho-
genesis of disease caused by Stx1, as evidenced by changes in
lethality. Pretreatment with rmTNF- protects mice from le-
thality caused by Stx1 and Stx2, while rmTNF- treatment
after Stx1 challenge slightly increases lethality. Mice were only
partially protected from increased lethality in the TNF--post-
treated animals by neutralizing both TNF- and Stx1. Finally,
the in vivo results do not correlate with previous reports dem-
onstrating the ability of TNF- to upregulate Gb3 expression
by endothelial cells in vitro.
Treatment of mice with TNF- alters Stx1-induced renal
histopathology. A major shortcoming of murine models of
Stx-mediated renal damage is the failure to fully recapitulate
the pathogenesis of human DHUS, in which pathology is
primarily localized to renal glomeruli. In mice, toxin-mediated
damage appears to be localized to renal tubules (50, 54). Mice
do, however, develop hallmark signs of DHUS, including
thrombocytopenia, microangiopathic hemolytic anemia, and
acute renal failure, when Stx2 is coadministered with LPS,
FIG. 3. TNF- pre- and posttreatment alter Shiga toxin 1-mediated lethality. Animals were injected with Stx1, Stx2, rmTNF-, or saline, as
indicated, via the intraperitoneal (i.p.) route. Treatment groups were categorized based on the timing of rmTNF- injection relative to toxin
exposure. (A) Mice pretreated with rmTNF- prior to Stx1 injection (TNF- pretreatment group). Mice were injected with 2.0 g rmTNF- 24,
6, or 1 h before the administration of 9 g/kg of Stx1 and monitored for morbidity. The graph represents the results of three independent
experiments using a total of 13 mice (n 	 13). Three asterisks denotes significance at P  0.001 compared to Stx1 treatment alone. (B) Mice
pretreated with rmTNF- prior to Stx2 injection (TNF- pretreatment group). Mice were injected with 2 g rmTNF- 24, 6, or 1 h before the
administration of 10 ng/kg of Stx2 and monitored for survival. The graph represents results of two independent experiments (n	 10). Two asterisks
denotes significance at P  0.01 compared to Stx2 treatment alone. (C) Mice receiving Stx1 prior to rmTNF- injection (TNF- posttreatment
group). Mice were given 9 g/kg of Stx1 and subsequently injected with rmTNF- 1, 6, and 24 h later and monitored for survival. The graph
represents results of two independent experiments (n 	 6). The asterisk denotes significance at P  0.05 compared to Stx1 treatment alone.
(D) Neutralizing antibodies were used to protect TNF--posttreated animals from increased Stx1 lethality. Briefly, mice were given either 4.0 g
anti-rmTNF- antibody or 60 ng anti-Stx1 antibody. One hour later, mice were challenged with 4.5 g/kg of Stx1 followed 1 h later by 2.0 g rmTNF-
and were monitored for survival during a 7-day period. The graph represents results of two independent experiments (n 	 10). An asterisk denotes
significance at P  0.05, and a double asterisk denotes significance at P  0.01 compared to TNF--posttreated animals. All statistical significance was
assessed by the log-rank (Mantel-Cox) test using Graphpad Prism version 5 for Mac OS X (Graphpad Software, San Diego, CA).
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suggesting that proinflammatory cytokine expression affects
the localization of renal tissue damage (19). We therefore
examined renal pathology in mice administered Stx1 alone or
treated with rmTNF- 24 h before or after toxin challenge. It
is important to note that histopathology at the 1- and 6-h pre-
and posttreatment time points also was examined; however, for
simplicity, only the 24-h time point is shown (Fig. 4). The
damage seen at earlier treatment times was consistent with
damage elicited by Shiga toxin exposure (data not shown).
Animals treated with saline were used as controls for normal
renal structure (Fig. 4E). The treatment of mice with rmTNF-
did not cause renal damage (Fig. 4A). Consistent with earlier
studies, the administration of Stx1 alone resulted in tubular
necrosis (Fig. 4B), and in all Stx1-plus-TNF- treatment
groups there was damage to tubules, as evidenced by tubular
swelling (Fig. 4D, star) and the sloughing of cells into the
lumen (Fig. 4C, star). The treatment of mice with rmTNF-
before toxin challenge (Fig. 4C), which is associated with in-
creased survival, did not result in significant changes in renal
pathology compared to that of animals treated with Stx1 alone
(Fig. 4B). In contrast, the treatment of mice with rmTNF-
after toxin treatment exacerbated pathology in the kidney.
Glomeruli in the TNF- posttreatment group appeared to be
hyperemic or occluded and were smaller in size with increased
Bowman’s capsule space (Fig. 4D, arrow) compared to glomer-
uli in Stx1-treated animals (Fig. 4B, arrow) or the TNF-
pretreatment group (Fig. 4C, arrow). The data are further
supported by the quantification of hyperemic/occluded versus
normal glomeruli by light microscopy. Total glomeruli were
counted per high-power field to show that equal numbers of
FIG. 4. TNF- pre- and posttreatment alter Shiga toxin 1-mediated renal histopathology. Mice were treated with rmTNF- alone (A), 9 g/kg
Stx1 alone (B), pretreated with rmTNF- 24 h before toxin (C), posttreated with rmTNF- 24 h after toxin challenge (D), or treated with saline
(E). Kidney halves were harvested 48 h after toxin administration and processed for H&E analysis. Slides were blinded, examined, and quantified
by a veterinary pathologist. Arrows in panels B, C, and D point to glomeruli; stars in C and D denote renal tubule damage. The magnification of
all images is40 (bar	 500 m). Glomerular quantification was done blinded by counting total glomeruli (F) versus hyperemic glomeruli (G) per
high-power field (10 fields were counted per slide). The experiment was repeated twice with a total of six mice. Statistical significance was assessed
by one-way ANOVA and Tukey’s multiple comparison post hoc test. An asterisk denotes significance at P  0.05, and three asterisks denotes
significance at P  0.001.
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glomeruli were counted in each experimental group (Fig. 4F).
Animals treated with Stx1 before TNF- exposure showed a
significant increase in hyperemic or occluded glomeruli (P 
0.05) compared to that of TNF--pretreated mice and mice
treated with Stx1 alone (Fig. 4G). Thus, renal pathology occur-
ring in mice treated with rmTNF- after toxin challenge was
greater in severity and involved glomeruli to a greater extent than
mice injected with Stx1 alone or treated with rmTNF- before
toxin challenge. The expansion of renal compartments damaged
in the TNF- posttreatment group may contribute to the accel-
erated mean time to death seen in this group.
Treatment of mice with TNF- alters Stx1-induced changes
in renal function and blood chemistries. DHUS is defined, in
part, by the loss of renal function. Therefore, we examined
indicators of renal function, blood urea nitrogen (BUN), and
serum creatinine in control mice, mice treated with rmTNF-
or Stx1 alone, or mice pre- or posttreated with rmTNF- and
Stx1 (Fig. 5). Because of the complexity of the experimental
protocol, we have chosen one TNF- treatment time in which
there was both significant survival and a significant increase in
lethality. The survival curves (Fig. 3A and C) show that there
was 90% survival by pretreating the mice with TNF- 6 h
before Stx1 administration. Additionally, when mice were
treated with TNF- 6 h after Stx1, there was 100% lethality.
Therefore, these experiments were conducted using the 6-h
pre- and posttreatment timeline. BUN levels of animals in-
fected with Stx1 alone rose to approximately 118 mg/dl, while
uninfected control and TNF--only levels remained within
normal limits of 21.33 and 21.86 mg/dl, respectively (Fig. 5A).
Mice treated with rmTNF- before Stx1 exposure also re-
mained within normal limits, approximately 25 mg/dl. Mice
treated with rmTNF- after Stx1 exposure had the greatest
increase in mean BUN levels, at approximately 150 mg/dl. This
same trend was seen with serum creatinine levels, with signif-
icant increases in Stx1 alone and rmTNF--posttreated ani-
mals and no significant changes in the TNF--pretreated ani-
mals (Fig. 5B). The administration of Shiga toxins may alter
other clinical factors in mice, such as numbers of circulating
neutrophils and lymphocytes (19). Therefore, complete blood
counts were conducted on samples collected from control and
treatment groups. There were significant increases in segmented
neutrophils in both Stx1 alone and TNF--posttreated animals
FIG. 5. Treatment of mice with TNF- alters Shiga toxin 1-induced changes in renal function and blood chemistries. Mice were treated with
saline, 9 g/kg Stx1 alone, rmTNF- alone, pretreated with rmTNF- 6 h prior to Stx1 exposure (TNF- pretreatment), or posttreated with
rmTNF- 6 h after Stx1 exposure (TNF- posttreatment). Forty-eight hours later, all groups were euthanized. Sera were collected and analyzed
for BUN (A) and creatinine levels (B), and the percentages of lymphocytes (C) and segmented neutrophils (D) were determined. The scatter plots
represent results of two independent experiments (n	 6). Statistical significance between all groups was assessed using the Kruskal-Wallis test with
Dunn’s multiple comparison post test. An asterisk denotes significance at P  0.05, and three asterisks denotes significance at P  0.001.
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compared to the levels for control animals (P  0.001 and P 
0.05, respectively) (Fig. 5C). Both groups treated with Stx1 alone
or posttreated with TNF- also presented with lymphocytopenia
more often than the controls (P  0.05); however, the TNF-
pretreatment and posttreatment groups were not significantly dif-
ferent from each other (Fig. 5D). Animals pretreated with
rmTNF- showed a slight decrease in circulating lymphocyte
numbers, which were not statistically significant compared to
those of uninfected controls or rmTNF--treated animals.
Treatment of mice with TNF- alters Stx1-induced cytokine
profiles. Cytokines are signaling proteins mediating a wide
range of physiological responses, including the activation of
innate and adaptive immunity, inflammation, and hematopoi-
esis. Many cytokines made early in response to infectious chal-
lenges, like TNF-, trigger the expression of multiple down-
stream cytokines. According to our data, the time at which the
cytokine TNF- initiates signaling cascades may play an im-
portant role in the mortality and pathogenesis of renal disease
caused by Shiga toxins. To address the role of cytokines po-
tentially induced by Stx1 and TNF- in the pathogenesis of
Stx1-induced renal failure, cytokine levels were measured in
renal tissue homogenates prepared from animals treated with
Stx1 alone and in TNF- pretreatment and posttreatment
groups. Because of the complexity of the experimental proto-
col, we have chosen one TNF- treatment time at which there
was both significant survival and a significant increase in le-
thality. The survival curves (Fig. 3A and C) show that there was
90% survival by pretreating the mice with TNF- 6 h before
Stx1 administration. Additionally, when mice were treated with
TNF- 6 h after Stx1, there was 100% lethality. Therefore,
these experiments were conducted using the 6-h pre- and post-
treatment timeline. A comparison of renal cytokine expression
in mice treated with toxin alone versus the TNF- pretreat-
ment group showed a rapid, transient fold increase in TNF-
and IL-1 expression in renal tissues of the pretreatment
group (Fig. 6); however, there were no statistically significant
effects on the other assayed cytokines. TNF- posttreatment
animals showed multiple differences in cytokine profiles (Fig.
6). The extensive fold change in TNF- levels at the first time
point probably was due to the exogenous administration of
rmTNF- 1 h prior to kidney harvesting; however, TNF-
expression remained significantly elevated up to 24 h after
rmTNF- injection. Injected rmTNF- appeared to induce
IL-1 production in the TNF- posttreatment group, which
remained significantly elevated up to 6 h posttreatment. Inter-
estingly, the levels of the anti-inflammatory cytokine IL-10
were significantly downregulated in the TNF- posttreatment
group beginning 24 h after rmTNF- injection. A similar pat-
tern of IFN- expression was apparent; that is, IFN- expres-
sion began to decrease 6 h after toxin treatment and remained
downregulated throughout the course of the experiment. Fi-
nally, in contrast to the rmTNF--pretreated animals, signifi-
cant differences in GM-CSF expression were detected 1 h after
rmTNF- injection. These data suggest that skewing the cyto-
FIG. 6. Comparison of renal cytokine expression in TNF--pretreated and TNF--posttreated animals. Mice were treated with either 9 g/kg Stx1
alone, with Stx1 6 h after rmTNF- exposure (TNF- pretreatment group), or with rmTNF- 6 h after Stx1 exposure (TNF- posttreatment group). At
various time points, kidneys were harvested and the expression of the cytokines TNF-, IL-1, IL-10, IFN-, and GM-CSF in renal tissue homogenates
was analyzed as described in Materials and Methods. The data shown are expressed as the fold change of the rmTNF- pretreatment group or the fold
change of the rmTNF- posttreatment group from results for Stx1 alone at each time point. The experiment was repeated twice with a total of six mice
in each group. Statistical significance between cytokine expression by Stx1-treated cells versus treatment groups at each time point was assessed using
one-way ANOVA with Tukey’s multiple comparison post test. An asterisk denotes significance at P 0.05, two asterisks denotes significance at P 0.01,
and three asterisks denotes significance at P  0.001 between the TNF- treatment group and Stx1 treatment only.
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kine response to a heightened proinflammatory and a lowered
anti-inflammatory state contribute to the increased mortality
and glomerular pathology seen in animals administered
rmTNF- after toxin exposure.
Treatment with TNF- alters Stx1-mediated tubular apop-
tosis in the murine kidney. Stx1 and Stx2 induce programmed
cell death or apoptosis in vitro and in vivo (49). Therefore, we
examined the capacity of Stx1 to elicit apoptosis in renal tissues
isolated from mice treated with Stx1 and in TNF- pre- and
posttreatment groups. It is important to note that TUNEL
staining at the 1- and 6-h pre- and posttreatment time points
also was examined; however, for simplicity, only the 24-h time
point is shown (Fig. 7). Mice administered Stx1 or rmTNF-
alone (Fig. 7B and C) showed low levels of apoptotic cells in
TUNEL-stained renal sections, which were not significantly
different from saline control tissues (Fig. 7A). TUNEL-posi-
tive cells appeared to be localized to renal tubules. The levels
of apoptotic cells in the TNF--pretreated animals remained
relatively low (Fig. 7D). Mice treated with rmTNF- after
initial toxin exposure (Fig. 7E) appeared to have higher num-
bers of apoptotic cells compared to mice treated with Stx1
alone or the TNF- pretreatment group. Data were quantified
by counting the number of TUNEL-positive cells in blinded
tissue sections for all treatment groups (Fig. 7F). When mice
were exposed to Stx1 alone or rmTNF- alone or were pre-
treated with rmTNF-, the average number of TUNEL-posi-
tive cells per high-power field remained relatively constant,
whereas mice posttreated with rmTNF- had a significant in-
crease (P  0.001) in TUNEL-positive cells.
DISCUSSION
While advancements in our understanding of the host innate
immune response in DHUS pathogenesis have been made
using cultured cells, the corroboration of these results using
animal models has proven problematic, since many small-ani-
mal models do not fully reproduce the pathology seen in hu-
mans with DHUS. Unlike humans, where the primary renal
vascular lesion is glomerular and may take weeks to develop,
mice develop damage to tubule epithelia and die within days of
the injection of purified Stx1 or Stx2 (50). Exposure to multiple
low doses of Stx2, or the injection of LPS with Stx2 into mice,
results in glomerular pathology and thrombocytopenia that
more closely mimic HUS in humans (19, 40). Thus, bacterial
products known to induce TNF- expression alter pathogene-
sis in the mouse model. Based on earlier studies showing that
TNF- upregulates toxin receptor expression on endothelial
cells in vitro, thereby sensitizing the cells to the lethal action of
the toxins (24, 34, 53), we predicted that the pretreatment of
mice with rmTNF- would manifest the toxin sensitization
FIG. 7. Treatment with TNF- alters Shiga toxin 1-mediated apoptosis in the murine kidney. Mice were treated with saline (A), rmTNF- alone
(B), Stx1 alone (C), rmTNF- 24 h before Stx1 exposure (pretreatment group) (D), or rmTNF- 24 h after Stx1 injection (posttreatment group)
(E). Kidneys were harvested 48 h after toxin administration and stained for the presence of apoptosis. (F) Apoptosis was quantified by counting
the numbers of TUNEL-positive cells per high-power field, with three fields per treatment group. Statistical significance between the groups was
assessed using one-way ANOVA and Tukey’s multiple comparison post test.
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phenomenon in vivo. Surprisingly, we found that animals pre-
treated with rmTNF- displayed decreased lethality when
challenged with Stx1 or Stx2, while animals that received ex-
ogenous rmTNF- after toxin exposure died faster than animals
given Stx1 alone. Increased lethality in the TNF- posttreatment
group was partially neutralized by the administration of anti-Stx1
and anti-rmTNF- antibodies. The partial protection seen with
neutralizing antibodies might be due to insufficient dosing or the
timing of antibody administration. The data suggest that the tim-
ing of exposure to TNF- relative to toxin exposure is a critical
determinant in the outcome of disease in mice.
Stx1 and Stx2 share general structural and functional prop-
erties and are roughly comparable in terms of in vitro cytotox-
icity when using toxin-sensitive cell lines such as Vero cells or
human umbilical vein endothelial cells. However, infections
with Stx2- or Stx1- and Stx2-expressing STEC are more likely
to progress to extraintestinal complications, and in vivo studies
using mice, gnotobiotic piglets, and baboons demonstrated
that the animals are more sensitive to lethality caused by Stx2
than that by Stx1 (7, 42, 50). A number of mechanisms may
contribute to this difference in lethality. Both toxin types bind
the glycolipid receptor Gb3 but with different dissociation con-
stants, so that Stx1 binds more avidly than Stx2 (28). Stx1 and
Stx2 have been shown to differentially translocate across po-
larized intestinal epithelial cell monolayers (14), suggesting
that differences in toxin uptake in the gut contribute to differ-
ences in lethality. Rutjes et al. (37) demonstrated the differ-
ential distribution of Stx1 and Stx2 in mice. Stx2 accumulated
to a greater extent in the murine kidney, while Stx1 was found
to be associated with the bone marrow of the spine and long
bones, nasal turbinates, and lungs. Furthermore, the serum
clearance rate of 125I-Stx2 was much slower than that of 125I-
Stx1 in mice. Human renal microvascular endothelial cells
were reported to be more sensitive to the cytotoxic action of
Stx2 than that of Stx1 (25). Suzuki et al. (46) showed that the
A subunit of Stx2, but not that of Stx1, contained a sequence
capable of binding the prosurvival molecule Bcl-2, which may
sensitize host cells to apoptosis induced by Stx2. However, we
have found, using human macrophage-like cells, that the apop-
tosis-inducing capacities of Stx1 and Stx2 are roughly compa-
rable (unpublished data). Finally, the cytotoxic activity of Stx2,
but not that of Stx1, was reported to be neutralized by binding
to the acute-phase protein human serum amyloid P (HuSAP)
(20). However, while HuSAP inhibits the binding of Stx2 to
Gb3-expressing murine neutrophils, it actually increases Stx2
binding to Gb3-negative human neutrophils (11). Despite
these differences in toxin translocation and distribution, we
show here that the rates of survival in mice and baboons given
Stx1 or Stx2 are similar; i.e., the animals are more sensitive to
the lethal action of Stx2, but the mean times to death are
prolonged compared to that for Stx1 (42). The delayed pro-
gression of lethality in Stx2-treated baboons is associated with
differences in renal pathology. Comparative studies exploring
renal pathology in Stx1- versus Stx2-treated mice are planned.
The phenomenon of protection provided by pretreatment with
TNF- before toxin challenge manifested in mice given Stx1 or
Stx2, suggesting that the early administration of TNF- is a
candidate for further study as an immunotherapeutic agent to
block disease progression.
All animals receiving purified Stx1 alone or Stx1 with
rmTNF- pretreatment showed signs of acute tubular necrosis
(Fig. 4B, C, and D) with evidence of tubular epithelial necrosis
and the sloughing of cells into tubule lumina (Fig. 4C, star),
while glomeruli were largely spared vascular damage (Fig. 4B
and 4C). Animals that received rmTNF- after toxin treatment
showed evidence of tubular damage but also showed occa-
sional glomerular pathology characterized by intraglomerular
hyperemia and glomerular hypertrophy (Fig. 4D). Thus, the
increased lethality we observed in animals that received
rmTNF- after toxin exposure was associated with increased
glomerular damage (Fig. 4G). The postmortem autolysis of
tissue specimens is a significant concern in histopathological
studies. It is important to note, therefore, that the renal tubule
pathology consistently detected in all animals receiving Stx1 in
the presence or absence of rmTNF- was not detected in
saline-treated controls, nor was it detected in renal specimens
collected from animals receiving rmTNF- alone. The fact that
the animals were sacrificed and kidney tissues were harvested
and processed in an identical manner strongly supports the
concept that renal tubular necrosis is toxin mediated and not
the result of postmortem autolysis or fixation artifacts, since
one would expect these changes to be present in all treatment
groups. The protection of animals by the administration of
rmTNF- before toxin challenge does not appear to involve
major differences in renal histopathology, i.e., tubular damage
is similar in animals given toxin alone and in the rmTNF-
pretreatment group. While differences in lethality noted as a
function of the timing of TNF- exposure were not correlated
with striking differences in renal pathology, it is possible that
differences in renal function manifest in the absence of gross
histopathological changes. Our data indicate clear differences
in renal function (BUN and serum creatinine levels) among
the treatment groups. Renal function was preserved in animals
receiving rmTNF- prior to intoxication, whereas decreased
renal function was evident in mice treated with Stx1 or Stx1
followed by rmTNF-. Lymphocytopenia and neutrophilia pre-
viously described in mice treated with Stx2 and LPS (19) were
noted in toxin-only groups; however, the changes in the TNF-
treatment groups were not statistically significant. rmTNF-
pretreatment prevented lymphocytopenia, although elevated
numbers of segmented neutrophils were detected in rmTNF-
-pretreated animals. Recently, Stearns-Kurosawa et al. (42)
showed that Stx1, but not Stx2, increased the expression of gran-
ulocyte-colony stimulating factor (G-CSF) in baboons. It would
be interesting to determine if a similar differential induction in
G-CSF exists in Stx1- and Stx2-treated mice and whether differ-
ences in granulocyte production account for the difference in
toxin lethal doses seen in mice. The maintenance of functional,
circulating lymphocytes may be a mechanism by which TNF-
pretreatment increases survival after Stx1 challenge.
Shiga toxins elicit cytokine and chemokine expression from
myeloid (12, 35, 51), epithelial (52, 55), and endothelial cells
(4, 27) in vitro, and clinical studies have reported elevated
cytokine levels in patients with HUS (15, 23). TNF- is known
to be an effective inducer of a number of cytokines, including
the autoinduction of its own expression (45). Taken together,
these data suggest that differences in renal cytokine expression
in animals receiving Stx1 alone compared to that with Stx1 and
rmTNF- contribute to differences in lethality. Fold changes in
cytokine expression in renal homogenates prepared from mice
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treated with rmTNF- prior to Stx1 (TNF- pretreatment
group) revealed transient increases in the proinflammatory
cytokines TNF- and IL-1 at early time points; however, no
significant changes were noted in the other assayed cytokines.
In animals intoxicated prior to receiving rmTNF- (TNF-
posttreatment group), we detected sustained higher fold
changes of proinflammatory cytokines, while the expression of
IL-10 and gamma interferon (IFN-) showed significant de-
creases compared to the levels at early time points. Thus,
increased lethality and glomerular histopathology detected in
animals receiving Stx1 prior to rmTNF- treatment are asso-
ciated with the increased expression of proinflammatory cyto-
kines and the decreased expression of the anti-inflammatory
cytokine IL-10 and the macrophage-activating cytokine IFN-.
Karpman et al. (16) used TUNEL staining to present evi-
dence of apoptosis in human renal tissue sections isolated from
HUS cases and in murine renal sections derived from animals
treated with Shiga toxins. We examined the capacity of
rmTNF- pre- or posttreatment to modulate Stx1-induced re-
nal cell apoptosis. Mice treated with Stx1 alone or pretreated
with rmTNF- prior to toxin showed relatively low numbers of
apoptotic cells, primarily in renal tubules. These data suggest
that the protective mechanism triggered by the early exposure
to rmTNF- does not alter the degree of apoptotic cell death
in renal tissues. When animals were treated with Stx1 before
rmTNF-, however, we detected many more apoptotic cells in
renal sections, suggesting that increased lethality correlates
with increased renal apoptosis.
Currently, there are no effective vaccines to prevent infec-
tions with Stx-producing bacteria, and there are no effective
therapeutic strategies to prevent the progression of disease
from the prodromal diarrheal phase to DHUS. We showed
that mice treated with a single dose of rmTNF- before chal-
lenge with purified Stx1 or Stx2 were protected from lethality.
Protection was associated with the maintenance of renal func-
tion and the preservation of normal numbers of circulating
lymphocytes. Protection did not correlate with major differ-
ences in renal histopathology, renal expression of cytokines,
neutrophilia, or differences in the degree of renal apoptosis.
We speculate that pretreatment with rmTNF- before Stx1
exposure rendered target cells more resistant to the effects of
Shiga toxins. One possible explanation of protection is a phe-
nomenon known as acquired cytoresistance. Zager et al. (56)
demonstrated that renal proximal tubule cells, when subjected
to an initial insult, such as the injection of LPS, may “prime”
the kidney and protect against a second insult. Honda et al.
(13) and Nath et al. (29) demonstrated that when the kidney is
preexposed to LPS, it can become resistant to nephrotoxin-
induced renal failure. Collectively, these studies are in accor-
dance with our findings and suggest that pretreating mice with
rmTNF- before toxin exposure protects the kidney from fur-
ther insult and injury. Mechanisms of cytoresistance may in-
volve the upregulated expression of stress proteins and changes
in membrane cholesterol levels (56). We have shown that Shiga
toxins will activate the stress-associated protein kinases JNK
and p38 (6), and the maintenance of lipid rafts has been shown
to be essential for toxin uptake and retrograde transport (8).
Another possible mechanism of protection afforded by
rmTNF- pretreatment is the modulation of toxin receptor
expression on the surface of target cells. Our preliminary stud-
ies suggest that rmTNF- downregulates membrane Gb3 ex-
pression on renal tubular epithelial cells by affecting the ex-
pression of enzymes involved in Gb3 biosynthesis (unpublished
data). In marked contrast to the protective effect of early
rmTNF- exposure, animals intoxicated first, followed by
rmTNF- administration, showed increased sensitivity to the
lethal action of Stx1 with a decreased mean time to death.
Increased lethality was associated with increased glomerular
damage, decreased renal function, increased proinflammatory
cytokine expression, the decreased expression of an anti-in-
flammatory and a macrophage-activating cytokine, and in-
creased renal apoptosis. In summary, the data suggest that the
early administration of TNF- is a candidate interventional
strategy meriting further study for the amelioration of renal
disease caused by Shiga toxins. However, caution must be
taken in any immunomodulatory approach to the treatment of
diseases caused by Shiga toxins, since our data suggest that the
timing of TNF- administration relative to intoxication is a
critical determinant in disease outcome.
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